Within hours after treatment with tocilizumab, Emily began to improve very rapidly.

在用托珠单抗治疗后的几个小时内，艾米丽开始迅速改善。

That's why last summer, when the FDA approved CAR T cells for leukemia, they also co-approved the use of tocilizumab to block the IL-6 effects and the accompanying CRS in these patients.

这就是为什么去年夏天， 当FDA批准CAR-T细胞治疗白血病时，他们还共同批准使用托珠单抗来阻断IL-6效应和伴随的CRS。